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Abstract
Anti-apoptotic Bfl-1 and pro-apoptotic Bax, two members of the Bcl-2 family sharing a similar structural fold, are classically
viewed as antagonist regulators of apoptosis. However, both proteins were reported to be death inducers following
cleavage by the cysteine protease m-calpain. Here we demonstrate that calpain-mediated cleavage of full-length Bfl-1
induces the release of C-terminal membrane active a-helices that are responsible for its conversion into a pro-apoptotic
factor. A careful comparison of the different membrane-active regions present in the Bfl-1 truncated fragments with
homologous domains of Bax show that helix a5, but not a6, of Bfl-1 induces cell death and cytochrome c release from
purified mitochondria through a Bax/Bak-dependent mechanism. In contrast, both helices a5 and a6 of Bax permeabilize
mitochondria regardless of the presence of Bax or Bak. Moreover, we provide evidence that the a9 helix of Bfl-1 promotes
cytochrome c release and apoptosis through a unique membrane-destabilizing action whereas Bax-a9 does not display
such activities. Hence, despite a common 3D-structure, C-terminal toxic domains present on Bfl-1 and Bax function in
a dissimilar manner to permeabilize mitochondria and induce apoptosis. These findings provide insights for designing
therapeutic approaches that could exploit the cleavage of endogenous Bcl-2 family proteins or the use of Bfl-1/Bax-derived
peptides to promote tumor cell clearance.
Citation: Valero JG, Cornut-Thibaut A, Juge ´ R, Debaud A-L, Gime ´nez D, et al. (2012) m-Calpain Conversion of Antiapoptotic Bfl-1 (BCL2A1) into a Prodeath Factor
Reveals Two Distinct alpha-Helices Inducing Mitochondria-Mediated Apoptosis. PLoS ONE 7(6): e38620. doi:10.1371/journal.pone.0038620
Editor: Gen Sheng Wu, Wayne State University School of Medicine, United States of America
Received May 14, 2011; Accepted May 9, 2012; Published June 20, 2012
Copyright:  2012 Valero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: JGV was recipient of doctoral fellowship from La Re ´gion Rho ˆne-Alpes. This work was supported by grants from the Silab-Jean Paufique Corporate
Foundation (France), La Ligue Contre le Cancer (Comite ´s de la Dro ˆme et du Rho ˆne), the Spanish MICINN (BFU2010-19118/BMC, financed in part by the European
Regional Development Fund), L’Institut National du Cancer (INCa poro-combo), Comple ´ment de dotation from UCBL Lyon 1, Programme CIBLE de la Re ´gion
Rho ˆne-Alpes and a collaborative French/Spanish project (EGIDE PHC PICASSO 17092SM; MEC, HF2007-0090). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jerome.kucharczak@ens-lyon.fr
. These authors contributed equally to this work.
Introduction
Proteins of the Bcl-2 family are key regulators of mitochondrial
outer membrane (MOM) permeabilization, a prerequisite to
cytochrome c release from mitochondria and activation of the
downstream apoptotic cascade that leads to cell demise [1,2]. The
Bcl-2 family comprises both anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w,
Bfl-1/A1 also named BCL2A1, Mcl-1 and Bcl2l10) and pro-
apoptotic (e.g., Bax, Bak) members that share three BCL-2
homology (BH) motifs in their primary structure (BH1, BH2 and
BH3), some anti-apoptotic members presenting an additional BH4
domain. Besides the multi-BH members, a class of proteins that
contains a single BH3 domain, the so-called BH3-only proteins,
also displays pro-apoptotic activity. Furthermore, many Bcl-2
family proteins contain a hydrophobic tail at their C-termini,
called transmembrane (TM) domain, which may be critical for
both subcellular localization and activity towards apoptosis.
Mechanistically, death inducers like Bax and Bak are known to
change conformation upon activation and oligomerize to form
pores in the MOM, thus allowing the release of cytochrome c and
other effectors of apoptosis from the mitochondria. In contrast,
prosurvival members counteract the Bax- and Bak-induced MOM
permeabilization, thus preserving the functional integrity of
mitochondria, while BH3-only proteins provide an additional
layer of complexity by activating either directly or indirectly Bax/
Bak in response to noxious signals [3]. Astonishingly, despite their
opposite effect on cell survival, both Bcl-2-like and Bax-like
multidomain proteins share a common 3D globular structure in
their water-soluble state, which also resembles that of some pore-
forming bacteriocins, such as colicins and diphtheria toxin [4,5].
By analogy with colicins, it was proposed that two central helices
(a5-a6 in Bax, Bcl-2 and Bcl-xL and a6-a7 in Bid) within
‘globular’ Bcl-2 family members may participate in membrane
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measurements of ion-channel activity in synthetic lipid membranes
[6,7,8,9]. Additional studies based on deletion mutants and site-
directed mutagenesis underscored the crucial role of these central
helices in the ion-channel activity, the release of cytochrome c and
apoptosis regulation by both pro- and anti-apoptotic proteins
[10,11,12,13]. More recently, reductionist approaches showed that
peptides corresponding to a5 and/or a6 of Bax can partly
reproduce the poration activity displayed by the full-length protein
in model membrane systems and mitochondria [14,15,16]. The
pores appear to be of the mixed lipidic-peptidic type
[14,15,17,18], similar to those of membrane-active, amphipathic
peptide antibiotics [19] and can be characterized as stable
equilibrium structures [18,20]. Interestingly, these studies have
also pointed out differences in the respective abilities of these
central helices to insert into model membranes or induce
mitochondrial cytochrome c release depending on the parent
protein from which they were derived (Bax, Bcl-xL or Bid),
providing clues to the functional divergence observed within the
family [14,16,21].
Besides regulating apoptosis through their mutual interactions,
many Bcl-2-related proteins are known to undergo N-terminal
protease-mediated truncation, a process that changes drastically
their activity. Indeed, the prosurvival factors Bcl-2, Bcl-xL and
Mcl-1 were shown to undergo caspase-dependent cleavage leading
in all cases to the release of a pro-apoptotic truncated fragment
[22,23,24,25]. A different class of proteases named calpains has
been reported to target both pro- and anti-apoptotic family
members for proteolytic cleavage. Incidentally, m-calpain has been
shown to cleave Bax N-terminally [26] to release a truncated
fragment presumed to behave like a BH3-only protein (similarly to
the caspase cleavage products of Bcl-2, Bcl-xL and Mcl-1) [27].
Notably, we and others previously demonstrated that the same
calpain converts prosurvival Bfl-1 into a death-promoting factor in
B cells through N-terminal truncation [28], although in this case
precise characterization of the cleavage sites/products is lacking.
In this paper, we have mapped biochemically the m-calpain
cleavage sites present on the Bfl-1 protein and identified the
potential death-promoting fragments of Bfl-1 that are generated
upon m-calpain digestion. The MOM-permeabilizing and death-
promoting abilities of the different membrane-active regions
present in the Bfl-1 truncated fragments were compared to that
of homologous domains in pro-apoptotic Bax using cell-based
assays and isolated mitochondria. Our data indicate that, although
both proteins are cleaved by the same protease, Bfl-1 being
converted into a potent pro-apoptotic factor, their toxic domains
have only limited overlap and induce apoptosis through dissimilar
mechanisms. The significance of these findings for the potential
applicability of Bax/Bfl-1-derived peptides as therapeutic agents is
discussed.
Results
Bfl-1 is Cleaved at the N-terminus by m-calpain in a way
Similar to Bax
Both Bax and Bfl-1 undergo m-calpain cleavage [26,28].
However, the sites targeted by the protease and the nature of
the subsequent cleaved fragments remained to be determined for
Bfl-1.
To characterize the precise cleavage sites in Bfl-1, GST-Bfl-1(1–
151) recombinant protein was digested by m-calpain and the
produced fragments were separated by SDS-PAGE and analyzed
by mass spectrometry (MS). A major band of ,28,000 Da
corresponding to the GST-containing N-terminal part of Bfl-1 was
detected. In addition, two fragments of ,12,000 Da and 17,500
Da were also found, suggesting that m-calpain targets Bfl-1 on two
major sites (Figure 1A, left panel). Samples corresponding to these
bands were digested by trypsin and the resulting peptides were
then analyzed by MS. Mass spectra reproducibly detected
a cleavage after L21 and Q22 for the top sub-band and after
F71 for the bottom sub-band. The residue Q22 was predicted with
a high score as a cleavage site in Bfl-1 by the CaMPDB program
[29]. This residue is located in a disordered linker, i.e. a type of
sites that often corresponds to preferentially scissible regions [30].
To further support the calpain cleavage sites, sub-bands were
sequenced using Edman degradation, which confirmed that Bfl-1
had been N-terminally cleaved between residues F71 and N72
(Figure 1A, right panel). Moreover, to exclude the possibility that
additional cleavage sites are present downstream of the F71/N72
residues, full length GST-Bfl-1(1–172) and GST-Bfl-1(1–151) were
treated with m-calpain and products were separated by SDS-
PAGE. Gels show that the size of the lower band corresponding to
the cleaved C-terminal part of the protein shifts upwards when full
length Bfl-1 is digested, therefore demonstrating that there is no
additional cleavage site after the F71–N72 residues (Figure S1).
No single substrate-binding/cleavage site has been defined for
calpains because these proteases display conformational prefer-
ence, implying that the region surrounding the cleavage site is
important for recognition by the protease. Thus, in order to test
whether mutation of the identified cleavage sites blocks proteolysis
by m-calpain, we generated a double deletion mutant of Bfl-1
lacking residues 20–25 and 69–74 (Bfl-1DD). As deletion of the
residues 20–25 occurs within the putative BH4 region of Bfl-1,
a domain critical for the cytoprotective activity of antiapoptotic
Bcl-2 proteins [31,32], we designed an additional mutant (Bfl-1SD)
in which the region surrounding the first cleavage site was
swapped with a structurally homologous region present in
BCL2L10, a close homologue of Bfl-1 that does not exhibit
a calpain cleavage site according to the CaMPDB database [29]
(Figure 1B, Figure S2). When lysates from 293T cells transiently
expressing comparable levels of GFP-Bfl-1 or GFP-tagged Bfl-1
mutants were treated with recombinant calpain, the double bands
corresponding to the N- or the C-terminal fragments of Bfl-1 were
visible only for the case of the wild type protein but not for any of
the two mutants (figure 1C). The transient expression of the Bfl-
1DD and Bfl-1SD mutants appeared to induce cell death both in
293T and Hela cells (data not shown and Figure S3) thus
precluding the establishment of stable cell lines to gain insights into
the underlying mechanisms.
Nevertheless, as the m-calpain-dependent cleavage of Bfl-1 was
observed both in vitro and for ectopically expressed Bfl-1 in cells,
we investigated whether such truncation of Bfl-1 could also be
detected in cells with high level of endogenous Bfl-1. We used
BJAB, a Diffuse Large B Cell lymphoma (DLBCL) cell line known
to express high levels of Bfl-1 mRNA and protein [33,34]. A
treatment with TNFa and CHX or staurosporine (STS), two
stimuli known to activate m -calpain in B cells induced the
appearance of a band at ,12 kDa, in agreement with the size
previously observed in vitro for the C-terminal truncated fragment
of Bfl-1. Importantly, the appearance of the cleaved fragment was
abrogated in presence of the calpain inhibitor ALLN (figure 1D),
demonstrating that m-calpain-mediated cleavage of Bfl-1 also
occurs with the endogenous protein. Altogether, these results
strongly suggest that Bfl-1 undergoes m-calpain-mediated trunca-
tion at two major sites; the first one at the end of helix a1, similar
to the cleavage in Bax, and the second one within helix a4 (before
the BH1 domain) (Figure 1E).
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family [31] and as the BH3 domain peptide of Bfl-1 displays no
binding activity against the anti-apoptotic Bcl-2 proteins [35], we
reasoned that it is unlikely that this region is involved in the
cytotoxic effect of m-calpain cleaved Bfl-1. Therefore, we focused
on the membrane-active fragments present on the truncated C-
terminal part of Bfl-1, as these regions were the most likely
candidates for playing a role in cell death induction. At an early
stage of the work, we generated GFP fusion constructs of Bfl-1
encompassing the C-terminal helices downstream the m-calpain
cleavage site, a region that covers the pore-forming domain (PFD)
and the carboxy-terminal 35 amino acids encoded by the last exon
(FE, final exon) (figure 1F, top panel). Cells transfected with GFP
or GFP-Bfl-1 showed no apoptotic features while GFP-Bax and
GFP-Bax-(PFD+FE) exhibited higher apoptotic rates. Unexpect-
edly, the GFP-Bfl-1 (PFD+FE) fusion protein that contains helices
downstream of the m-calpain cleavage site (but is devoid of any
BH3 domain) induces apoptosis akin to the homologous miniature
of Bax (figure 1F, bottom panels).
Overall, these results indicate that the larger truncated Bfl-1
fragment containing a5t oa9 helices is likely responsible for the
cytotoxic effect of Bfl-1 observed upon m-calpain-mediated
cleavage.
Bfl-1 a5/a9-containing Constructs Induce Apoptosis via
Bax/Bak-dependent and Independent Mechanisms
To compare the contribution of each structural domain of Bfl-1
and Bax to apoptosis induction, the putative membrane-active a-
helices of Bfl-1, as well as homologous helices within Bax, were
cloned in fusion with GFP (Figure 2A). The different constructs
were transfected into HT1080 cells and GFP-positive cells were
analyzed by FACS following annexin V labeling. As expected, cells
expressing GFP-Bax showed apoptotic features. The expression of
the a5 helices from Bax and Bfl-1 both induced significant cell
death, Bax-a6 having a similar toxic effect but not Bfl-1-a6. In
addition, the C-terminal helices of both proteins showed markedly
different effects. Indeed, Bax-a9 produced only weak apoptotic
induction, while Bfl-1-a9 displayed a sharp increase in apoptotic
rate (Figure 2B), which was comparable to that of Bfl-1-a5. From
these results it is clear that both helices a5 and a9 of Bfl-1 have
strong and independent cell death-inducing activities.
To further investigate the mechanisms by which the different
constructs promote cell death, we used wild type MEF (WT) and
Figure 1. m-calpain cleaves Bfl-1 at two major sites in its N-terminus and releases a large C-terminal fragment with cytotoxic
activity. (A) GST-Bfl-1(1–151) was digested with recombinant m-calpain in vitro and the fragments were separated by SDS-PAGE (left panel). Bands
corresponding to cleaved products (arrows) were analyzed by mass spectrometry (MS). A higher concentration of recombinant GST-Bfl-1(1–151) was
treated with m-calpain, products were separated by SDS-PAGE and blotted to PVDF (right panel). A sub-band (asterisk) was excised and subjected to
Edman degradation, which indicated that Bfl-1 had been N-terminally cleaved between residues F71 and N72. (B) Schematic representation of the
wild type Bfl-1 protein showing the location of the identified m-calpain cleavage sites (asterisks, upper sequence), of mutant Bfl-1 protein with a 6
aminoacids deletion surrounding the two cleaved residues (Bfl-1DD, middle sequence), and of mutant Bfl-1 in which the region overlapping the first
cleavage site was swapped with a structurally homologous region in Bcl2L10 (Bfl-1SD, bottom sequence) (C) Confirmation of the two calpain
cleavage sites identified in Bfl-1 using noncleavable mutants. 293T cell lysates expressing GFP-tagged Bfl-1 constructs were exogenously treated with
m-calpain. Lysates containing equal amount of GFP-tagged Bfl-1 proteins were separated by SDS-PAGE and analyzed by western blot with an anti-GFP
antibody to detect the full length protein and N-terminal truncated fragments and with a polyclonal anti-Bfl-1 antibody to detect C-terminal
truncated fragments. Upper and lower panels represent two independent experiments with different time of exposure. (D) BJAB cells were cultured
with or without treatment with TNF/CHX in the presence or absence of the calpain inhibitor ALLN. Lysates were separated by SDS-PAGE and the
presence of a cleaved fragment was assayed by western blot using an anti-Bfl-1 antibody. (E) Secondary structure of Bfl-1 in which the nine helices of
the protein are represented by boxes along with the different BH domains (left panel).The two cleavage sites mapped in (A) are indicated. A
comparison with the previously published m-calpain cleavage site in Bax is also shown [26] (bottom sequence). 3D structure of Bfl-1 (2VM6) [31] and
position of the different cleaved sites (red circles) are indicated. The different Bcl-2 Homology domains are colored in yellow (putative BH4), red (BH3),
green (BH1) and blue (BH2). (F) FACS assays of Annexin V staining in HT1080 cells. Chimeric GFP constructs encoding GFP alone, or fusions of GFP
with full-length Bfl-1 or Bax or with the various membrane-active a-helices corresponding to the C-terminal part of Bfl-1 or Bax, i.e. a5, a6 (PFD, pore
forming domain) and a9 (FE, final exon) are represented. The a-helical topology of Bax and Bfl-1 corresponds to the structures solved in aqueous
environment [31,50]. Transfected cells were stained for phosphatidylserine exposure using Cy3-conjugated Annexin V and the percentage of
apoptotic GFP-expressing cells was determined by FACS 24 hours post transfection (right panel). Death of GFP-expressing and staurosporine (STS)-
treated cells were also monitored as controls. Graphs shown are representative of three independent experiments.
doi:10.1371/journal.pone.0038620.g001
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Cell death quantification by FACS showed that Bfl-1-a5 induced
cell death in WT but not in DKO cells. This pattern is different
from that of Bax-a5 and Bfl-1-a9, since both have a potent toxic
effect regardless of Bax/Bak expression. Similarly, a6 helices of
Bfl-1 and Bax exhibited again strong differences, as Bfl-1-a6 was
inefficient for inducing cell death while Bax-a6 was a potent cell
death inducer in both cell types. To further evaluate the
contribution of each helix of Bfl-1 and Bax for the induction of
apoptosis, GFP-tagged constructs were transfected into either WT
or DKO MEF and cell lysates were subsequently analyzed by
immunoblotting. Samples expressing comparable levels of GFP-
tagged proteins were assayed for caspase 3 activation as a marker
of apoptosis (figure 2D). While Bax-a5 and Bax-a6 induced strong
caspase 3 cleavage, regardless of the presence of Bax and Bak, Bfl-
1-a5 induced caspase 3 activation only in WT MEFs. In contrast,
Bfl-1-a6 failed to trigger caspase 3 activation in both cell lines.
Finally, Bfl-1-a9 induced massive caspase 3 activation in both WT
and DKO MEF cells, but Bax-a9 had no significant effect
(Figure 2D). Taken together, these data demonstrate that in-
dividual membrane-active helices from Bfl-1 have different
abilities to induce cell death when compared among each other
(Bfl-1-a5, Bfl-1-a9.Bfl-1-a6, Bfl-1-a1) or with homologous
fragments on Bax (Bax-a6.Bfl-1-a6; Bfl-1-a9.Bax-a9). The data
also show that cell death induction by Bfl-1-a5 operates through
a mechanism that depends on endogenous Bax/Bak, while the
action of Bax-a5, Bax-a6 and Bfl-1-a9 is independent of the
intrinsic expression of these proteins in the cultured cells.
To assess the contribution of each helix in the context of the
whole C-terminal truncated part of Bfl-1, we expressed larger
GFP-fused constructs that comprise a5, a6 and a9 helices of Bfl-1
in WT and DKO MEF cells. Interestingly, the a5-a6o ra5-a6-a9
GFP chimeras of Bfl-1 behaved like a5 alone as they showed
a strong apoptotic effect and appeared to require Bax/Bak to
induce cell death (Figure S4). These data suggest that although a9
of Bfl-1 has a toxic potency by itself, in fragments where the a9
helix is present together with a5, like in the C-terminal part of
Figure 2. The ectopic overexpression of GFP-tagged Bfl-1-a5/a9 and Bax-a5/a6 fragments induces cell death but with distinct Bax/
Bak requirements. (A) Chimeric GFP proteins used in this study. GFP-tagged constructs encoding GFP alone, or fusions of GFP with full-length Bfl-1
or Bax or with the various membrane-active a-helices of Bfl-1 or Bax, i.e. a1, a5, a6 and a9, are represented. The a-helical topology of Bax and Bfl-1
correspond to the structures solved in aqueous environment [31,50]. Because the structures of the membrane-bound forms of these proteins are
unknown, we designed sequence boundaries that extend a few residues beyond the a-helical regions in the structures of the water-soluble forms. (B)
FACS assays of Annexin V staining in HT1080 cells. Transfected cells were stained for phosphatidylserine exposure using Cy3-conjugated Annexin V
and the percentage of apoptotic GFP-expressing cells was determined by FACS. Histograms represent the percentage of GFP-expressing cells binding
Annexin V (upper panel). Assays were performed in triplicate (error bars correspond to standard deviations). Staurosporine (STS) treatment was
included for comparison. (C) FACS histogram showing Annexin-V staining of MEF (left panel) and MEF-DKO cells (right panel) expressing the different
GFP-tagged constructs described in (A). GFP-transfected cells treated with staurosporine (STS) or left untreated were used as controls. Assays were
performed in triplicate (error bars correspond to standard deviations). (D) Expression and analysis of the various GFP-tagged proteins in mammalian
cells. Western Blot analyses on transiently transfected MEF (top panel) or MEF DKO cells (bottom panel) at 24 h post-transfection. Proteins were
separated by SDS-PAGE and the presence of fusion proteins with the correct size was tested by immunoblot with anti-GFP antibody. Analysis of
caspase-3 activation below each panel shows the cleaved 17 kDa product indicative of activated caspase-3.
doi:10.1371/journal.pone.0038620.g002
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action that drives cells into apoptosis.
Homologous Membrane-active Helices from Bfl-1 and
Bax Exhibit Similar Subcellular Localization
To study the mechanism by which membrane-active fragments
derived from Bfl-1 and Bax proteins induce apoptosis, we
compared the subcellular distribution of the different GFP-fused
constructs by confocal fluorescence microscopy. Expression of the
fusion proteins yielded abundant and intense GFP fluorescence in
transfected WT or DKO cells (Figure 3). GFP alone showed
a diffuse localization. In contrast, full length Bfl-1 as well as Bfl-1
helices exhibited a partial (a1) or a strong (a5, a6 and a9) clustered
staining corresponding to MitoDsRed-labeled mitochondria. In
parallel, the subcellular localization of the homologous helices of
Bax and Bfl-1 was compared. We observed that Bax-a1 exhibited
a weak mitochondrial staining similar to that of Bfl-1-a1. The
other a-helices from Bax (a5, a6 and a9) targeted GFP to the
mitochondrial membranes with the same strong clustered pattern
observed for the corresponding Bfl-1 helices. However, the
membrane active helices that had shown no toxic effect, i.e. Bfl-
1-a1 and Bfl-1-a6, were addressed to mitochondria as were those
that induced cell death. Therefore, although each helix of Bax and
Bfl-1 shares a similar propensity to target mitochondria, additional
intrinsic differences exist that explain the differential cytotoxicity of
the helices. Importantly, the absence of endogenous Bax and Bak
did not affect the subcellular localization of the various GFP
constructs (figure 3), suggesting that the amphipathic character-
istics of Bfl-1 or Bax membrane-active helices may be sufficient to
target the fusion proteins to mitochondria independently of Bax
and Bak. Taken together, these results show that the differential
toxic effect observed between Bfl-1 helices is not due to differential
localization of the expressed chimeric constructs.
Synthetic Peptides Derived from Helices a5, a6o ra9o f
Bfl-1 Induce Cytochrome C Release from Mitochondria
with Different Efficacy and Mechanisms
To explore the effect of Bfl-1-derived fragments on mitochon-
drial membrane permeabilization, isolated mitochondria were
used as a test system which closely resembles the in cellulo
functional context. To this end, different synthetic peptides were
directly incubated with mitochondria purified from both WT and
DKO MEF or iBMK cells at different concentrations and times.
We monitored the permeabilization of mitochondria by assaying
the presence of cytochrome c in the pelleted fraction (mitochon-
dria) and in the supernatant. In parallel, detection of the
mitochondrial matrix-resident protein Hsp70 was used to validate
the proper isolation of mitochondria. Among the peptides derived
from Bfl-1 central helices, the Bfl-1-a5 peptide was able to release
efficiently cytochrome c at a 10 mM concentration and 5 min
incubation time on mitochondria from two different WT cells.
Importantly, the release was significantly delayed when mitochon-
dria from two types of Bax/Bak double KO cells were used,
indicating that poration of the mitochondria upon Bfl-1-a5
treatment is modulated by endogenous Bax and/or Bak proteins
(figure 4, upper panels). In contrast, the Bfl-1-a6 peptide failed to
induce cytochrome c release in these experiments, even when high
peptide concentrations and incubation times were used (figure 4,
middle panels).
Next, our in vitro assays showed that cytochrome c release
occurred massively at low concentrations when a Bfl-1-a9 peptide
was used and that mitochondria were totally depleted of
cytochrome c at 25 mM even at short times of peptide exposure.
Unexpectedly, the presence of the Hsp70 protein was detected in
both the mitochondrial and the supernatant fractions at all three
peptide concentrations. In parallel, the same mitochondria
extracts treated with DMSO for 60 minutes revealed that both
Hsp70 and cytochrome c were in the pellet, ruling out that
a contamination occurred between the mitochondria and the
supernatant fractions during the experimental procedure (figure 4,
lower panels). Importantly, when a Bax-a9 peptide was applied to
mitochondria, concentration-dependent cytochrome c release was
observed in WT cells but not in DKO cells although the HSP70
marker was properly distributed into the pellet fraction. These
results indicate that Bfl-1-a9 uses a distinct mechanism to porate
mitochondria compared to Bfl-1-a9.
To investigate further the mechanism by which Bfl-1-a9
permeabilizes mitochondrial membranes, we assayed the distribu-
tion of MnSOD, another matrix-resident protein (like Hsp70), and
of Hexokinase 1 (HK1), an integral outer membrane protein. After
treatment with Bfl-1-a9 at concentrations in the range 2.5–25 mM,
MnSOD was found both in the pelleted and supernatant fractions,
in a way similar to Hsp70. In sharp contrast, the membrane
resident protein HK1 was restricted to the pellet (figure 5). These
results indicate that up to 2.5 mM concentration Bfl-1-a9 was able
to porate both the outer and inner mitochondrial membranes.
However, it does not appear to exert an extensive disruption
action (detergent-like action [36] over membranes since HK1 was
not solubilized. Notably, at 0.5 mM concentration, the peptide was
still able to induce a strong release of cytochrome c even at short
incubation times (figure 5), but the integrity of the mitochondrial
inner membranes was somehow preserved as Hsp70 was only
found in the pellet in that case. Taken together, these results show
that Bfl-1-a9 has a high potency to permeabilize mitochondrial
membranes, as demonstrated by the induced leakage of high
molecular weight proteins such as MnSOD or Hsp70 from the
mitochondrial matrix to the cytosol. Moreover, this peptide
behaves differentially to porate the MOM depending on the
concentration used.
Discussion
The mechanism by which pro- and anti-apoptotic members of
the Bcl-2 family operate within the MOM governs the leaking of
apoptogenic factors from the mitochondria and finally the ‘live-or-
die’ fate of the cell. Interestingly, despite opposite effects on
apoptosis and wide differences in amino acid sequences, ‘multi-
BH’ Bcl-2 family proteins share a similar helical bundle fold that
resembles the pore-forming domains of some bacterial toxins
[37,38]. Although many 3D structures of multidomain Bcl-2
proteins are now resolved [39], the structural determinants that
are key elements to the functional differences between pro- and
anti-apoptotic members remain largely unknown. In this paper,
we have compared the various membrane-active domains of anti-
apoptotic Bfl-1 with their homologous helices found in pro-
apoptotic Bax with respect to their ability to induce cytochrome c
release from isolated mitochondria, to target GFP to mitochon-
drial membranes and to induce cell death. Our results clearly show
that structural domains distinct from the BH3 are able to induce
cell death and therefore represent an alternative way for cleaved
Bcl-2-related proteins to fulfill their cytotoxic effect. In addition,
extensive comparison of these domains shows that homologous
regions behave differently in their ability to induce mitochondrial
permeabilization and have different molecular requirements (i.e.
presence of endogenous Bax or Bak) for inducing apoptosis
depending on whether they derive from Bfl-1 or Bax.
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38620A striking example comes from our findings that helix a6 of Bfl-
1 is unable to induce cell death and to release cytochrome c
whereas the corresponding helix on Bax has strong cytotoxic
properties [40,41]. Consistent with this, we have previously
reported that helix a6 of anti-apoptotic Bcl-xL does not insert
efficiently into purified microsomal membranes [21] and is not
endowed with the capacity to induce cytochrome c release from
purified mitochondria [16] contrary to the equivalent helix in Bax.
In contrast, we found that helices a5 from both Bax [16,41] and
Bfl-1 (this study) were individually sufficient to induce cell death.
However, quite unexpectedly, Bfl-1-a5 (but not Bax-a5) [41]
appeared to require Bax/Bak for both its cytochrome c release and
death-inducing activities. The origin of this different behavior is
not clear but may be related to the fact that, while Bax-a5 has
been shown to form Bax-like pores in model membranes
[14,17,18], full length Bfl-1 was reported to selectively interact
with endogenous Bak (but not Bax) to suppress apoptosis [42].
This observation raises the possibility that Bfl-1-a5 could have the
capacity to stimulate the membrane-permeabilizing function of
Bak through direct physical contact. Alternatively, Bfl-1-a5 may
be responsible for functional Bax or Bak activation by an indirect
pathway. Furthermore, Bfl-1-a5 can also be distinguished from the
homologous segment on Bcl-xL, since a peptide corresponding to
this latter helix was not able to induce mitochondrial permeabi-
lization (in spite of a good ability to insert within lipid membranes)
[16,21]. Overall, these findings imply that subtle yet important
differences have emerged during evolution not only between
Figure 3. Subcellular localization of the GFP-tagged, Bfl-1/Bax-derived (poly)peptides. MEF (left panels) and MEF DKO (right panels) cells
were co-transfected with mitoDsRed plasmid (encoding DsRed2 fused to the mitochondrial targeting sequence from subunit VIII of human
cytochrome c oxidase) and the GFP-tagged constructs. Subcellular distribution was analyzed by confocal microscopy 24 h after transfection. Confocal
images showing GFP (green) and MitoDsRed (red) fluorescence. The DNA staining dye Topro-3 (blue) was used to visualize the nuclei. In merged
images, the yellow color shows the co-localization of GFP and MitoDsRed at mitochondria. Scale bar, 10 mm.
doi:10.1371/journal.pone.0038620.g003
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members but also within the anti-apoptotic sub-group.
The sharpest difference between the homologous membrane-
active regions under study comes from the intriguing behavior
of Bfl-1-a9 that differs from all the other helices. Indeed, we
observed that Bfl-1-a9 induced the release of cytochrome c at
a concentration as low as 0.5 mM (i.e. at lower concentrations
than the other Bcl-2-like-derived peptides used in our studies).
Figure 4. Bfl-1-derived peptides have different abilities to permeabilize the MOM of mitochondria isolated from cultured cells.
Peptides were incubated at different concentrations (10 mM and 25 mM) with isolated mitochondria for the indicated times (5, 15, 30 and 60 min) and
the release of cytochrome c was monitored by immunoblot (IB). MitoHsp70 (mHsp70) was used as control indicative of equal-loading and proper
isolation of the pellet fraction containing mitochondria (Mito) in comparison to the supernatant fraction (SN). Cytochrome c release assays were
performed using iBMKW2 (wild type) and iBMKD3 (double KO Bax/Bak) for all tested peptides. For Bfl-1-a5, wild type MEF and MEF DKO (Bax/Bak 2/
2 double KO) cells were used in parallel.
doi:10.1371/journal.pone.0038620.g004
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the mitochondrial matrix at higher doses, in a Bax/Bak
independent manner. Such a membrane permeabilizing activity,
including the concentration dependence, is reminiscent of the
action of cationic amphipathic antimicrobial peptides [43,44,45].
It also resembles the action of Bax-a5 and Bax-a6 peptides on
synthetic lipid membranes, for which larger pores at increasing
peptide-to-lipid ratio have been described [15]. At least for the
cases of Bax-a5 [20] and the antimicrobial peptide magainin
[46] it has been shown in experiments with giant unilamelar
vesicles that pores are large upon the initial stage of peptide
binding to membranes. However, after some time the pores
equilibrate to a stabilized, reduced size. This kinetic trace of
pore formation might be modified depending on peptide
concentration to allow the release of larger molecules at
increasing amounts of peptide bound to membranes. An
alternative explanation might be a detergent- like (or solubiliz-
ing) action, exerted specifically at high peptide concentrations
and by means of which big proteins are released after extensive
breaking of the membrane [36,47]. However, we consider this
unlikely, since the integral membrane protein Hk1 was never
observed in the supernatant of mitochondrial permeabilization
assays. Membrane-destabilizing properties for Bfl-1-a9 have
already been hinted upon by previous reports, and might be
associated with the peculiar distribution of charged residues in
the C-terminal end of Bfl-1 that confers a strong amphipathic
character compared to the typical hydrophobic stretch (TM)
found in other Bcl-2 proteins [48,49]. Interestingly, canonical
Bcl-2-like TM domains and Bfl-1-a9 were postulated to have
likely independent evolutionary origins [48]. On the other hand,
the pro-apoptotic activity of such peptide, acting directly on the
lipid membrane and regardless the expression of Bax or Bak,
suggests that it could be used to design a therapeutic strategy to
kill a number of tumor cells in which Bax or Bak has been
inactivated (see also below).Similar to Bfl-1-a5, Bax-a9 was
found to promote cytochrome c release from purified mito-
chondria in a Bax/Bak-dependent manner. It is possible that
this peptide competes with the a9 helix of full-length Bax that is
engaged in its BH1-3 hydrophobic cleft [50], leading to
activation of the endogenous Bax protein by conformational
change. However, other factors may prevent MOM permeabi-
lization within cells, since this region was unable to induce cell
death when expressed as a GFP fusion polypeptide.
Aside from evolutionary and mechanistic considerations, the
interest of the reductionist strategy used here also lies in the
identification of minimal motifs able to disrupt the mitochondrial
Figure 5. The Bfl-1-a9 peptide induces mitochondrial permeabilization through a membrane-destabilizing mechanism. Bfl-1-a9
peptide was incubated for the indicated times with mitochondria at lower concentrations (0.5 mM and 2.5 mM, top panels) and previously used in
figure 4 (10 mM and 25 mM, bottom panels). The release of cytochrome c and the expression of MitoHsp70 were monitored as in figure 4, combined
with the detection of the external membrane associated protein hexokinase 1 (HK1) and the matrix-contained protein MnSOD.
doi:10.1371/journal.pone.0038620.g005
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cancerous cells. To date, our work identified four different
candidate peptides for further studies as potential therapeutic
agents: Bfl-1-a5, Bfl-1-a9 (this study and [48]), Bax-a5 [41] and
Bax-a6 [16,41]. Of note, the synthetic Bax-a5 peptide was found
to trigger (when fused to a cell-penetrating peptide) caspase-
dependent apoptosis of cancer cells in vitro and in vivo [41],
demonstrating both the feasibility and effectiveness of this
approach. However, such biologically active peptides have to be
exogenously administered and should therefore be conjugated to
a homing device to achieve selective tumor targeting. An
interesting alternative would be to activate the proteolytic cleavage
of Bax or Bfl-1 specifically in tumor cells. In that respect, we
demonstrated here that m-calpain is able to cleave Bfl-1 in its N-
terminal part in vitro within the same region as previously observed
in cellulo [28]. In both cases, m-calpain truncation of Bfl-1 leads to
the generation of a death fragment that comprises the cytotoxic a5
and a9 helices but is devoid of the BH3 domain, contrary to the
other prosurvival Bcl-2 proteins (Bcl-2, Bcl-xL and Mcl-1), for
which caspase cleavage produces a pro-apoptotic fragment whose
death activity mainly depends on the integrity of the BH3 domain
[23,25,51]. Although further studies are warranted in cellulo to
determine whether the cleavage at the amino-acid 71 in Bfl-1 is
the major m-calpain site these results suggest that calpain-
truncated Bfl-1 may promote apoptosis through a5/a9-mediated
MOM permeabilization, and not as a BH3-only molecule [35].
Because Bfl-1 is endogenously overexpressed in many tumor cells,
including chemoresistant Diffuse Large B-cell lymphoma, Hogd-
kin’s Reed Stenberg cells and melanoma cells [52,53,54,55,56], it
would be interesting to design molecules which can activate m-
calpain specifically in those cancer cells in order to convert Bfl-1
from an anti-apoptotic protein to a mitochondria-permeabilizing
factor able to trigger cancer cell suicide.
Materials and Methods
Peptides and Drugs
The different peptides used for this study were prepared by
solid-phase synthesis as reported [14] in an Applied Biosystems
ABI 433A Peptide synthesizer (Foster City, CA, USA) using Fmoc
chemistry and Tentagel S-RAM resin (Rapp Polymere, Tu ¨bingen,
Germany; 0.24 mEq/g substitution) as a solid support. Peptides
were purified using a C18 semi-preparative reversed-phase
column (Merck, Darmstadt, Germany) by HPLC, to a .95%
purity, and their identity was confirmed by Mass Spectrometry.
Peptide concentrations were determined from UV spectra using
a Jasco spectrophotometer (Jasco, Tokyo, Japan). The amino acid
sequences of the peptides are shown in Table S2. Recombinant
TNFa (Sigma) was used at 10 ng/ml and cycloheximide (Sigma) at
10 mg/ml. Pre-treatment with the calpain inhibitor ALLN
(calbiochem) was performed during 30 min at 20 mM.
Antibodies
Primary antibodies were as follows: mouse monoclonal Anti-
mitochondrial-HSP70 (Abcam), polyclonal anti-Bfl-1 (Abcam),
anti-GFP mouse monoclonal antibody (Roche), anti-cleaved
caspase-3 rabbit polyclonal antibody (Cell Signaling Technology),
anti-a-tubulin (Santa Cruz Biotechnologies), anti-actin (Sigma),
anti-cytochrome c antibody (Pharmingen), anti-HK1 (Santa Cruz
Biotechnologies), anti-MnSOD (Stressgen). HRP-conjugated goat
anti-mouse and goat anti-rabbit secondary antibodies (Roche)
were used as secondary antibodies. Western Blot analysis was
performed according to standard procedures. SuperSignal West
Femto Chemiluminescent Substrate (Pierce) was used for detection
of endogenous Bfl-1.
Cell Culture
HT1080 cells were obtained from the European Collection of
Cell Cultures, MEF and MEF DKO (Bax/Bak 2/2) mouse
embryonic fibroblasts were obtained from Dr. Douglas Green’s
laboratory (St Jude Children’s research Hospital) and were
cultured as previously reported [57]. iBMK W2, iBMK D3
(Bax/Bak 2/2) baby mouse kidney cells were cultured as
previously described [58]. BJAB cells were obtained from the cell
collection facility of the UMS3444/US8 (CelluloNet Lyon,
France) and cultured in RPMI supplemented with 10% FBS.
For transient transfection, cells were seeded at a density of 10
5 cells
per 35 mm plate and allowed to grow for 24 h before transfection
with plasmids using the Lipofectamine2000 (Invitrogen) according
to the manufacturer’s recommendation. For each transfection
3 mg of plasmid DNA was used.
In vitro Cleavage Assays of Recombinant GST-Bfl-1 and
Mapping of the Bfl-1 Cleavage Sites
Recombinant GST-Bfl-1(1–172) or GST-Bfl-1(1–151) were
produced in bacteria as previously described [49]. For mapping
Bfl-1 cleavage sites, 6 mg of recombinant protein were incubated
for 60 min at 30uC with 7 ml of porcine m-calpain (Calbiochem) in
40 mlo fm-calpain buffer (30 mM TrisHcl pH 7.5, 750 mM
CaCl2, 1.5 mM DTT). The different reactions were run on 4–
12% NuPAGE Novex (Invitrogen) with MES buffer according to
the manufacturer protocol. For digestion of ectopically expressed
GFP-tagged Bfl-1 proteins, the constructs were transfected in
293T cells using Lipofectamine 2000 (Invitrogene) and cells were
lysed in RIPA buffer without EDTA but supplemented with serine
protease inhibitor AEBSF (1 mM). Lysates containing equivalent
amount of GFP-Bfl-1 fusion proteins were incubated in calpain
buffer in the presence or absence of m-calpain (0.2 u) for 45 min at
30uC. Reaction was stopped with 1 ml of EDTA (0.5 M).
Samples (gel pieces) were reduced with 60 mL of 10 mM DTT
in 50 mM NH4HCO3 for 15 min at 50uC. Alkylation was
performed with 60 mL of 55 mM iodoacetamide in 50 mM
NH4HCO3 for 15 min at room temperature in the dark. The gel
pieces were dried using 200 mLo fC H 3CN, protein-containing gel
pieces were treated with 0.3–0.5 mg of trypsin (sequence grade,
Promega) for 45 min at 50uC. A second extraction step was
performed using 30 mLo faH 2O/CH3CN/HCOOH (30/68/2;
v/v/v) mixture for 30 min at 30uC, and finally all extracts were
pooled and dried in a vacuum concentrator and resuspended in
0.1% trifluoroacetic acid (15 ml).
Mass spectrometry was performed using a Q-Star XL nanoESI
Quadrupole/time-of-flight tandem mass spectrometrer, nanoESI-
qQ-TOF-MS/MS (Applied Biosystems), coupled to an online
nanoliquid chromatography system (Famos, Switchos, and Ulti-
mate from Dionex). The chromatographic separation of peptides
was performed in a C18 PepMap micro-precolumn (5 mm; 100 A ˚;
300 mm65 mm; Dionex) and a C18 PepMap nano-column
(3 mm; 100 A ˚;7 5mm6150 mm; Dionex). After injection (1 mL
injection volume, pick-up mode, in a 15 mL injection loop),
samples were adsorbed and desalted on the pre-column with
aH 2O/CH3CN/trifluoroacetic acid (98/2/0.05; v/v/v) solvent
mixture for 3 min at 25 mL/min flow rate. The peptide separation
was developed using a linear 30 min gradient from 0 to 60% B,
where solvent A was 0.1% HCOOH in H2O/CH3CN (95/5) and
solvent B was 0.1% HCOOH in H2O/CH3CN (20/80) at
,200 nL/min flow rate. MS data were acquired automatically
using Analyst QS 1.1 software (Applied Biosystems). The MS and
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a trypsin autolysis peptide at m/z 842.510 [M + H]
+ and m/z
421.759 [M +2H]
2+. Screening was achieved by the paragon
method from the Protein-PilotH database-searching software
(Applied Biosystems).
To determine the m-calpain-induced site, 70 mg of GST-Bfl-
1(1–151) were digested in 160 ml of reaction with 40 mlo f
recombinant m-calpain for 4 hours. Edman degradation of samples
was performed on a Procise-492 sequencer (Applied Biosystems,
Foster City, Cal, USA) using standard PVDF cycles conditions.
Analysis and identification were done through in-line microbore
reversed-phase chromatography (140 C Microgradient System,
Applied Biosystems, Foster City, Cal, USA), UV detection @
269 nm, integration and calculation with 610A software (Applied
Biosystems, Foster City, Cal, USA).
Molecular Cloning
The oligonucleotides (Sigma-Proligo) that were used to prepare
the different constructions are indicated in Table S1. A double
PCR method was used to generate Bfl-1DD and Bfl-1SD mutants
using the primers listed in Table S1. All constructions were
subcloned into pGEM-T Easy (Promega) and subsequently into
XhoI and KpnI sites of pEGFP-C1. The sequence of all constructs
was verified by automated sequencing (GEXbyWeb).
Confocal Microscopy Analysis
Cells were fixed in 4% paraformaldehyde, permeabilized in
0.1% Triton X-100 for 3 minutes, and treated with TO-PRO-3
iodide (final 2 mM, Molecular Probes) before mounting in a drop
of anti-bleaching medium. Confocal analysis was performed on
a Zeiss confocal microscope (LSM510) (LePecq, France) with
a plan apochromat 6361.4 oil immersion objective. Images were
collected under identical non-saturated conditions after multiple
scans (, 8 sections per cell).
Measurement of Cell Death and Viability
Hoechst/PI labeling of cells to detect apoptotic and necrotic cell
death were performed as described previously [59]. Hoechst
33342 and PI were from Molecular Probes (Invitrogen). Cytotox-
icity assays were performed in triplicates. Cell death was quantified
by Annexin-V-Cy3 (BioVision Inc.) staining according to manu-
facturer’s protocols, followed by flow cytometric analysis using
a FACScan (Becton Dickinson). Data were processed using the
CellQuest Pro (version 4.0) software.
Cytochrome C Release Assays
Purified mitochondria were prepared from iBMK W2, iBMK
D3, MEF WT or MEF DKO cells. Briefly, cells were mechanically
broken using a 2 ml glass/glass dounce homogenizer (Kontes).
Two rounds of 60 and 10 strokes were used for iBMK cells and
two rounds of 30 strokes were used for MEF cells. Homogenates
were cleared in MB buffer (10 mM Hepes pH 7.5, mannitol
210 mM, sucrose 70 mM, and EDTA 1 mM) at 1500 g and the
mitochondria were spun down at 10,500 g. For cytochrome c
release assays, 20 mg of purified mitochondria were resuspended in
RB buffer (125 mM Kcl, 5 mM succinate and 0.5 mM EGTA)
supplemented with protease inhibitor cocktail (Roche). Peptides at
different final concentrations were added to the samples and the
incubations were carried out at 30uC under agitation (300 rpm).
At the indicated time points, samples were spun down at 10,500 g
for 5 min at 4uC, supernatants and pellets were recovered and
analyzed by immunoblotting for the different markers.
Supporting Information
Figure S1 SDS-PAGE patterns of products from m-
calpain-treated GST-Bfl-1(1–151) and GST-Bfl-1(1–172).
Recombinant full length Bfl-1(1–172) and C-terminal truncated
Bfl-1(1–151) were treated with m-calpain in vitro and cleaved
products were separated by SDS-PAGE. Predominant C-terminal
truncated product due to cleavage at F71/N72 site is detected
(black arrow) and shifts when full length Bfl-1 protein is digested
(white arrow). Cleaved products were confirmed by MS/MS.
(TIF)
Figure S2 Identification of the Bfl-1 homologous se-
quence in BCL2L10 overlapping the first m-calpain site.
Alignment of Bfl-1 and Bcl2L10 N-terminal primary sequences.
Homologous sequences in Bcl2L10 surrounding the first cleavage
site of Bfl-1 was determined (Box) to design Bfl-1 swapped mutant
(Bfl-1SD). The disordered strech following alpha 1 helix of Bfl-1 is
indicated with an asterisque.
(TIF)
Figure S3 m-calpain resistant mutants of Bfl-1 have
a toxic effect when expressed in Hela cells. Top panels:
Hela cells were transfected with GFP-tagged Bfl-1 constructs (wt,
DD or SD) and fluorescence was observed using an inverted
microscope 20 hours post transfection. Images are representative
of the total field. Middle panels: quantification by FACS of the
GFP-expressing Hela cells 20 hours post transfection. Results
shown are representative of three independent experiments.
Bottom panel: FACS assays of Annexin V staining in Hela cells.
Transfected cells were stained for phosphatidylserine exposure
using Cy3-conjugated Annexin V and the percentage of apoptotic
GFP-expressing cells was determined by FACS. Assays were
performed in triplicate and a graph representative of the
experiment is shown.
(TIF)
Figure S4 Ectopic expression GFP-tagged C-terminal
fragments of Bax and Bfl-1 induces cell death in wt and
DKO MEF cells. Graphs showing cell death (bottom panel)
measured by Annexin-V staining of MEF and MEF-DKO cells
expressing the different GFP-tagged constructs described in the
upper panel. GFP-tranfected cells treated with staurosporine (STS)
or left untreated were used as controls.
(TIF)
Table S1 Sequence of oligonucleotide primers used for
this study.
(TIF)
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